Veru Dividend per Share

What does Veru do? Veru, Inc. generates revenue primarily through its Commercial segment, which focuses on FC2, a female condom product designed to prevent unintended pregnancy and sexually transmitted infections. The company's Research and Development segment develops multiple oncology and urology drug products, including VERU-111, VERU-100, and Zuclomiphene Citrate, targeting prostate cancer and breast cancer. These pipeline products are under clinical development and not yet commercialized. The Commercial segment's FC2 is sold to healthcare providers, distributors, and consumers seeking contraceptive and STI protection solutions. The Research and Development segment's drug candidates are not yet marketed, so revenue from this segment currently comes from partnerships or grants, though the business description does not specify such sources. Veru, Inc. operates in two segments: Commercial and Research and Development. The Commercial segment's FC2 product is the company's sole marketed product, while the Research and Development segment focuses on developing VERU-111, VERU-100, and Zuclomiphene Citrate for prostate cancer and breast cancer treatment. VERU-111 targets microtubules by crosslinking and disrupting alpha and beta tubulin subunits, and VERU-100 is a peptide formulation addressing limitations of androgen deprivation therapies for advanced prostate cancer. Zuclomiphene Citrate is part of the prostate cancer pipeline but lacks further detail in the description. The company's revenue streams are currently limited to FC2 sales in the Commercial segment, with no indication of revenue from the Research and Development segment's pipeline products. FC2 is marketed to healthcare providers, distributors, and end consumers for contraceptive and STI prevention purposes. The business description does not mention any other products, partnerships, or revenue sources beyond FC2 and the R&D pipeline. Veru is one of the most popular companies on Eulerpool.